Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ANKDD1A is a protein-coding gene located at chromosome 15q22.31 encoding a protein with nine ankyrin repeats and a death domain. Ankyrin repeats are motifs that mediate protein–protein interactions, while the death domain is associated with apoptosis and inflammatory signaling. ANKDD1A acts as a tumor suppressor in glioblastoma, primarily under hypoxic conditions. It directly interacts with factor inhibiting HIF1α (FIH1), regulating the transcriptional activity and stability of HIF1α, an important factor in cellular adaptation to hypoxia. By upregulating FIH1, ANKDD1A decreases glucose uptake, lactate production, inhibits autophagy, and induces apoptosis in GBM cells. ANKDD1A is frequently hypermethylated in gliomas, suggesting its role as a tumor-specific epigenetic biomarker and potential therapeutic target[1][4][6][7][9][11][12].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ankyrin repeat and death domain-containing protein 1A (ANKDD1A).